Renal Cell Carcinoma News
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
In a study, cytoreductive nephrectomy was not independently associated with improved survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors.
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
Higher birth weight and overweight in childhood found to predict an increased risk of renal cell carcinoma in adulthood, a large Danish study found.
The cancer field is not immune to the challenges of out-of-network and surprise billing.
Better renal function preservation is associated with decreased cancer-specific death risk among patients who have an estimated glomerular filtration rate (eGFR) below 85 mL/min/1.73 m2 after surgery for organ-confined renal cell carcinoma, a study found.
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies for mRCC.
The investigators observed significantly higher postoperative CTC counts in the open radical nephrectomy group compared with the other 3 groups in the study.
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.